source
- Eli Lilly to buy psychedelics biotech AtaiBeckley for $2.8 billionEli Lilly announced it will acquire AtaiBeckley, a biotech focused on psychedelic therapies for mental health, for an upfront cash payment of $2.8 billion. The purchase adds a new dimension to Lil…
- Eli Lilly to acquire AtaiBeckley in up to $3.8 billion deal, entering psychedelics marketEli Lilly announced it will buy AtaiBeckley, offering $6.75 per share for the company’s common stock. The transaction includes an upfront commitment of about $2.8 billion and a contingent value rig…